# Targeting Inflammation, Oxidative Stress, and the Central Nervous System > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/targeting-inflammation-oxidative-stress-and-the-central-nervous-system/ > **Published:** 2026-06-16T07:19:08-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:21-04:00 > **Clinical Summary:** Evidence-based clinical overview of cannabis anti-inflammatory oxidative stress CNS mechanisms and current gaps in human trial data for neurological disease. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDNeurologyMental HealthSafetyPolicyPain Clinical Summary This review examines the pharmacological mechanisms by which broad-spectrum cannabis and related natural products modulate neuroinflammation and oxidative stress, two pathological processes implicated in neurodegenerative diseases, psychiatric disorders, and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) syndromes. Cannabis-derived compounds, particularly [cannabinoids and terpenes](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), exhibit anti-inflammatory and antioxidant properties through multiple pathways including [cannabinoid receptor signaling](https://cedclinic.com/cannabis-brain-volume-study-cognitive-benefits/), direct free radical scavenging, and modulation of glial cell activation. The authors synthesize evidence suggesting that the entourage effect of whole-plant cannabis products may provide greater neuroprotective benefit than isolated cannabinoids alone, with potential applications in conditions such as Alzheimer’s disease, multiple sclerosis, and treatment-resistant depression. However, the review emphasizes that preclinical and emerging clinical evidence, while promising, requires rigorous human trials to establish efficacy, optimal dosing, and safety profiles before routine clinical integration. For clinicians considering cannabis in patients with neuroinflammatory or neurodegenerative conditions, this work provides mechanistic rationale for cautious exploration while underscoring the need for individualized patient assessment and ongoing clinical monitoring until higher-quality evidence emerges. Dr. Caplan’s Take “The mechanisms described here around cannabinoids and neuroinflammation are biologically plausible and worth tracking, but we’re still largely in the preclinical phase with these particular targets, so I’m careful not to overstate what we can do clinically right now based on this work alone. What I tell my patients is that we have some solid observational and small human data supporting cannabis for specific conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) and certain seizure disorders, but claims about broadly ‘targeting inflammation’ in the CNS need more rigorous human evidence before they become part of standard clinical practice.” Clinical Perspective 🧠 While preclinical evidence suggests cannabinoids may modulate inflammatory and oxidative stress pathways relevant to neurological conditions, the translation from in vitro and animal models to human clinical benefit remains uncertain and inconsistently demonstrated. The heterogeneity of cannabis preparations, variable cannabinoid and terpene profiles, and lack of standardized dosing regimens complicate efforts to establish reproducible therapeutic windows, and most human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) remain limited in scope and sample size. Notably, [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in patients with central nervous system disorders carries potential risks including cognitive effects, drug-drug interactions (particularly with antiepileptic or psychiatric medications), and exacerbation of certain conditions like psychosis that may offset putative anti-inflammatory benefits. Clinicians should remain cautious about recommending cannabis for inflammatory or oxidative stress-related CNS conditions outside established indications like chemotherapy-related nausea or specific seizure disorders, while acknowled 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Targeting%20Inflammation%2C%20Oxidative%20Stress%2C%20and%20the%20Central%20Nervous%20System%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59309)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59309)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Targeting%20Inflammation%2C%20Oxidative%20Stress%2C%20and%20the%20Central%20Nervous%20System%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59309)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Endocannabinoid System Identified as Therapeutic Target for Pancreatitis](https://cedclinic.com/endocannabinoid-system-identified-as-therapeutic-target-for-pancreatitis/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://link.springer.com/collections/bjfbfcffje](https://link.springer.com/collections/bjfbfcffje) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).